Texas Tech University Health Sciences Center Partners with Deep 6 AI
Texas Tech University Health Sciences Center (TTUHSC) and Deep 6 AI announced a collaboration, collaborating to integrate artificial intelligence (AI) within TTUHSC's electronic medical record (EMR) system.
TTUHSC will use Deep 6 AI to match patients to their clinical trials in real time. This process will allow researchers to find the right patients for their trials, which will reduce the workload on their staff. By using these AI tools, TTUHSC researchers will ultimatey give more patients access to participate in clinical trials and will be able to use any resulting therapies to treat patients.
Deep 6 AI uses natural language processing to search through structured and unstructured EMR data points, such as physician notes, lab reports, outpatient notes, radiology reports, genomics results, and pathology reports, to match patients to the ideal clinical trials. This process simplifies patient recruitment and allows administrators to focus on patient care and managing the trials.
Reference
Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical Trials. (2023, August 1). Cision PR Newswire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
